MOUNTAIN VIEW, Calif. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) for Disease Activity (primary endpoint)
MOUNTAIN VIEW, Calif. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: Piper Sandler 32nd Annual Virtual Healthcare Conference On-demand
-- New Drug Application (NDA ) accepted for review by U.S. Food and Drug Administration (FDA) for avacopan in ANCA -associated vasculitis with PDUFA goal date of July 7, 2021 -- -- Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA) for avacopan in
-- Study Showed T reatment with Avacopan A chieved Statistical Superiority in Sustaining Remission at 52 Weeks and G reater I mprovement in R enal F unction C ompared to the Prednisone Group -- MOUNTAIN VIEW, Calif. , Nov. 06, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.
Companies have completed the EU regulatory application for marketing approval of avacopan Regulatory submission based on positive data from the pivotal P hase-III ADVOCATE trial of avacopan ST. GALLEN , Switzerland and MOUNTAIN VIEW, Calif. , Nov. 03, 2020 (GLOBE NEWSWIRE) -- Vifor Fresenius
MOUNTAIN VIEW, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's third quarter 2020 financial results will be released after market close on Monday, November 9, 2020 . ChemoCentryx executive management will host a conference call and
-- Avacopan demonstrates statistically significant dose-dependent improvement in HiSCR (Hidradenitis Suppurativa Clinical Response) vs. placebo in pre-specified Hurley Stage III (severe HS) patients at 12 weeks; numerical improvement observed with avacopan treatment in overall study population --
-- FDA sets PDUFA goal date of July 7, 2021 -- MOUNTAIN VIEW, Calif. , Sept. 17, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for avacopan, an orally-administered
MOUNTAIN VIEW, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 1:30
